As Biohaven reported its fourth quarter and full-year 2021 earnings to investors, the biotech unveiled two new deals a licensing deal with a Big Pharma and an acquisition of a smaller company.
Bioha… [+3404 chars]
In two separate moves, Biohaven seeks to repurpose failed Bristol Myers/Roche Duchenne drug while buying out small biotech – Endpoints News